Market Size

CelLBxHealth’s ultimate objective is the widespread adoption of the Parsortix^® Platform into treatment centers which specialize in the diagnosis and treatment of cancer patients.

Cancer remains one of the world’s largest and fastest-growing healthcare challenges. According to the Global Cancer Observatory (WHO), in 2022 there were an estimated 19 million new cancer cases, with almost 10 million cancer-related deaths globally. The number of people living with cancer is expected to significantly rise due to ageing populations, environmental factors and improved survival rates.

The growing demand for less invasive, repeatable and real-time diagnostic tools is driving the demand for liquid biopsy technologies. CTCs  have the potential to provide clinically valuable information that complements traditional tissue biopsy, mRNA and  ctDNA analysis.

CelLBxHealth’s vision is to establish circulating tumor cells  within standard-of-care diagnostic workflows, alongside tissue biopsy and circulating tumor DNA .

Potential applications for CTC analysis include:

1. therapy selection and companion diagnostics
2. treatment monitoring and assessment of therapeutic response
3. disease progression and recurrence monitoring
4. biomarker discovery and translational research
5. pharmaceutical drug development and clinical trial support
6. development of laboratory-developed tests (LDTs)

CelLBxHealth’s partner-led commercial strategy is focused on accelerating adoption of CTC analysis through integration with established laboratory workflows and strategic collaborations with leading diagnostics, pharmaceutical and life sciences organisations.